Latest News and Press Releases

Want to stay updated on the latest news?

Sign into Reader Account Create Reader Account

July 08, 2026 09:45 ET | Source: MAIA Biotechnology, Inc.

MAIA Biotechnology Reports Strong Initial Efficacy Data in Third-Line Non-Small Cell Lung Cancer from Phase 2 THIO-101 Part C Expansion Trial

90.5% interim disease control rate (DCR) observed with combination therapy Initial Part C efficacy observations align with previously reported THIO-101 clinical activity despite a more heavily...
July 07, 2026 08:30 ET | Source: Oragenics, Inc.

Oragenics Achieves Full Activation of Australian Phase IIa Trial Network — All Three Sites Now Enrolling

Company also advances U.S. regulatory pathway for ONP-002 with FDA Type B meeting request All three Australian Phase IIa trial sites — Mackay Base Hospital, Alfred Health, and Royal Adelaide Hospital...
July 01, 2026 10:00 ET | Source: Shoreline Recovery Center

How Meaningful Work Supports Long-Term Sobriety

San Diego, CA, July 01, 2026 (GLOBE NEWSWIRE) -- For many working adults, the monotony of a 9 to 5 can feel like an annoying cycle of alarm clocks, commutes, meetings, and deadlines. It becomes an...
June 30, 2026 08:30 ET | Source: Moleculin Biotech, Inc.

Moleculin Reports Positive Phase 2/3 MIRACLE Interim Results, With Annamycin Complete Remission Rates 3-fold Greater than Control

Both Annamycin dose arms outperformed control on the primary endpoint of complete remission (CR): 43% and 36% versus 12% — reported on a full intent-to-treat (ITT) basis with no patient...
June 18, 2026 08:31 ET | Source: GRI Bio, Inc.

GRI Bio Secures FDA Orphan Drug Designation for GRI-0621 (Tazarotene) in Idiopathic Pulmonary Fibrosis

Designation highlights significant regulatory milestone and provides a potential pathway to seven years of U.S. market exclusivity LA JOLLA, CA, June 18, 2026 (GLOBE NEWSWIRE) -- GRI Bio, Inc....
June 18, 2026 08:05 ET | Source: Scienture Holdings, Inc.

SCIENTURE Expands Arbli™ Payor Coverage and Commercial Access, Adding Approximately 12.5 Million Covered Lives Nationwide

Broader pharmacy access, channel expansion, and payer coverage position Arbli™ for increased prescription volume and revenue growth COMMACK, NY, June 18, 2026 (GLOBE NEWSWIRE) -- SCIENTURE...
June 15, 2026 13:36 ET | Source: Nordicus Partners Corporation

Nordicus Partners Corporation Corporate Update

Orocidin's QR-01 demonstrates efficacy in two preclinical periodontitis models; micro-CT confirms reduced bone lossPhase IIa clinical trial in patients planned H1 2027 at the University of...
June 11, 2026 08:30 ET | Source: Vivos Inc.

Vivos Inc. Announces Receipt of Washington State Radioactive Materials License for IsoPet® Manufacturing

Kennewick, WA, June 11, 2026 (GLOBE NEWSWIRE) -- Vivos Inc. (OTCQB: RDGL), a medical device company pioneering Precision Radionuclide Therapy™ (PRnT) for the treatment of cancerous tumors, is...
June 11, 2026 03:00 ET | Source: ALK Abello

Anaphylaxis management is falling short in 2026 – EAACI data suggest EURneffy, the only needle-free nasal adrenaline spray, could help close the gap

Over half (54%) of adults at risk of anaphylaxis admit they have been without their adrenaline auto-injector (AAI) when needed—and nearly 40% do not carry one regularly (n=1,238 ).1HCP survey data...
June 09, 2026 08:21 ET | Source: BCC Research LLC

Advanced Municipal Water Treatment Technologies Market to Reach $61.5 Billion by 2030, Driven by Stringent PFAS Regulations

How advanced treatment technologies help municipalities improve water quality, meet compliance requirements and address declining freshwater resources.